Evaluation of salivary flow rate and gustatory function in HIV-positive patients with or without highly active antiretroviral therapy

Neha Verma; Ranjitkumar Patil; Vikram Khanna; Vandana Singh; Anurag Tripathi

doi:10.4103/ejd.ejd_289_16

European Journal of Dentistry, Table of Contents

CC BY-NC-ND 4.0 · Eur J Dent 2017; 11(02): 226-231
DOI: 10.4103/ejd.ejd_289_16

Original Article

Dental Investigation Society

Evaluation of salivary flow rate and gustatory function in HIV-positive patients with or without highly active antiretroviral therapy

Authors

Neha Verma

¹Department of Oral Medicine and Radiology, Faculty of Dental Sciences, KGMU, Lucknow, Uttar Pradesh, India
Ranjitkumar Patil

¹Department of Oral Medicine and Radiology, Faculty of Dental Sciences, KGMU, Lucknow, Uttar Pradesh, India
Vikram Khanna

¹Department of Oral Medicine and Radiology, Faculty of Dental Sciences, KGMU, Lucknow, Uttar Pradesh, India
Vandana Singh

¹Department of Oral Medicine and Radiology, Faculty of Dental Sciences, KGMU, Lucknow, Uttar Pradesh, India
Anurag Tripathi

¹Department of Oral Medicine and Radiology, Faculty of Dental Sciences, KGMU, Lucknow, Uttar Pradesh, India

Abstract

ABSTRACT

Objectives: The aim of this study is to evaluate the salivary flow rate and gustatory changes in HIV-positive patients on highly active anti-retroviral therapy (HAART) and without HAART. We also correlated CD4 count and salivary flow rate and gustatory function in both groups. Methods: Sample size for each group was thirty. After obtaining informed consent, we measured salivary flow rate using Schimer's method and gustatory function using four tastants (sweet, sour, bitter, and salty) of different concentrations. The readings were recorded at 0 month, 2^nd, 4^th, and 6^th month interval. The data obtained was statistically analyzed. Results: The mean salivary flow rate was decreased more in Group I as compared to Group II. The mean identification score for sweet, salty, sour, and bitter was significantly higher in Group II than Group I. The mean detection threshold score for sweet, salty, sour and bitter taste was comparatively higher in Group I than Group II. The Pearson's correlation analysis showed inverse relation between age and salivary flow rate in Group II. No significant correlation was observed in CD4 count and salivary flow rate. Conclusion: Along with routine oral health appraisal in seropositive patients, evaluation of salivary flow rate, and taste abnormalities should also be considered an integral part of patient assessment.

Key words:

Gustatory function - highly active anti-retroviral therapy - salivary flow rate - seropositive patients

Full Text

References

REFERENCES
1 Global Statistics. 2014 Available from http://www.unaids.org [Last accessed on 2015 Aug 26].
2 Palmisano L, Vella S. A brief history of antiretroviral therapy of HIV infection: Success and challenges. Ann Ist Super Sanita 2011; 47: 44-8
3 Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res 2010; 85: 1-18
4 Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2012; 2: a007161
5 Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis. et al Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001; 28: 445-9
6 Diz Dios P, Scully C. Antiretroviral therapy: Effects on orofacial health and health care. Oral Dis 2014; 20: 136-45
7 Raja JV, Rai P, Khan M, Banu A, Bhuthaiah S. Evaluation of gustatory function in HIV-infected subjects with and without HAART. J Oral Pathol Med 2013; 42: 216-21
8 Islam NM, Bhattacharyya I, Cohen DM. Salivary gland pathology in HIV patients. Diagn Histopathol 2012; 18: 366-72
9 López-Verdín S, Andrade-Villanueva J, Zamora-Perez AL, Bologna-Molina R, Cervantes-Cabrera JJ, Molina-Frechero N. Differences in salivary flow level, xerostomia, and flavor alteration in Mexican HIV patients who did or did not receive antiretroviral therapy. AIDS Res Treat 2013; 2013-613278
10 Navazesh M, Mulligan R, Komaroff E, Redford M, Greenspan D, Phelan J. The prevalence of xerostomia and salivary gland hypofunction in a cohort of HIV-positive and at-risk women. J Dent Res 2000; 79: 1502-7
11 Johar N, Proctor GB, Kumar R. A comparative study of salivary compostion of HIV seropositive patients on HAART and not on HAART. J Indian Acad Oral Med Radiol 2011; 23: 29-32
12 Lin AL, Johnson DA, Stephan KT, Yeh CK. Alteration in salivary function in early HIV infection. J Dent Res 2003; 82: 719-24
13 Pavithra S, Ranganathan K, Rao UK, Joshua E, Rooban T, Kumarasamy N. Impact of highly active antiretroviral therapy on salivary flow in patients with human-immuno deficiency virus disease in Southern India. J Oral Maxillofac Pathol 2013; 17: 17-22
14 Nittayananta W, Talungchit S, Jaruratanasirikul S, Silpapojakul K, Chayakul P, Nilmanat A. et al. Effects of long-term use of HAART on oral health status of HIV-infected subjects. J Oral Pathol Med 2010; 39: 397-406
15 Kumar JV, Baghirath PV, Naishadham PP, Suneetha S, Suneetha L, Sreedevi P. Relationship of long-term highly active antiretroviral therapy on salivary flow rate and CD4 Count among HIV-infected patients. J Oral Maxillofac Pathol 2015; 19: 58-63
16 Glick M, Muzyka BC, Lurie D, Salkin LM. Oral manifestations associated with HIV-related disease as markers for immune suppression and AIDS. Oral Surg Oral Med Oral Pathol 1994; 77: 344-9
17 Bretz WA, Flaitz C, Moretti A, Corby P, Schneider LG, Nichols CM. Medication usage and dental caries outcome-related variables in HIV/AIDS patients. AIDS Patient Care STDS 2000; 14: 549-54
18 Heald AE, Pieper CF, Schiffman SS. Taste and smell complaints in HIV-infected patients. AIDS 1998; 12: 1667-74